Yucatán Probes Rituximab Medication After Pediatric Reactions

Mérida, Yucatán — The Yucatán Ministry of Health has announced that a sanitary investigation is currently underway concerning the distribution of the medication Rituximab 500 mg/50 ml, lot 5445250607, which was acquired from the company SANTEK HEALTH S.A. de C.V.

The medication was administered at the General Hospital Dr. Agustín O’Horán to two patients from the Pediatric Rheumatology Service. Both patients subsequently presented mild adverse reactions. No serious complications have been reported to date.

During the corresponding documentary review, inconsistencies were identified in the medication's sanitary records and analytical certificates. In accordance with safety protocols, the Ministry immediately ordered the suspension of its use, secured the lot, and formally notified the Federal Commission for the Protection against Sanitary Risks (Cofepris). The federal commission is now conducting its own corresponding investigation.

According to preliminary findings, the detected irregularities could constitute crimes against health as outlined in article 464 Ter of the General Health Law. These pertain to the alleged falsification, adulteration, and marketing of falsified or altered medications. Such acts are punishable by prison sentences and financial fines, as they represent a direct threat to public health.

The Yucatán Ministry of Health reiterated its commitment to transparency, legality, and patient safety. It will continue to collaborate closely with federal authorities for the complete clarification of the case and the application of corresponding sanctions.

The Ministry reports that the patients remain under medical observation, evolving favorably and without major complications. The Yucatán Ministry of Health assures that it will apply the full weight of the law.